Breaking News, Collaborations & Alliances

NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm

Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines to develop and manufacture AAV Therapeutics.

By: Rachel Klemovitch

Assistant Editor

NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C&GT), has granted a non-exclusive technology license to Recipharm’s Advanced Therapies (ATMP) division (ReciBioPharm) to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines. NewBiologix provides cGMP-ready, high-yield, viral particle-producing cell lines and manufacturing technologies for deve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters